METHOD OF DETERMINING THE AVERAGE RATE OF LIVER FIBROSIS FORMATION IN PATIENTS WITH CHRONIC HEPATITIS B+C Russian patent published in 2023 - IPC A61B8/08 

FIELD: medicine; therapy; hepatology; infectious diseases.

SUBSTANCE: invention can be used to determine the average rate of formation of liver fibrosis in patients with chronic hepatitis B+C (CHB+C). The results of transient elastometry of the liver, APRI and Charlson indices of the patient are evaluated as the difference between the results of the last and previous measurements, divided by the number of years that have passed since the last measurement for each indicator. Then they are compared with the calculated values of the average rate of formation of liver fibrosis in CHB + C per year, which, according to elastometry, is 1.7 kPa, the APRI index is 0.2 points, taking into account the influence of concomitant diseases according to the Charlson index — 0.4 points. If a patient with CHB+C has an excess in one of the three indicators, the rate of formation of liver fibrosis is considered high and antiviral therapy is carried out. If all the results in a patient with CHB+C are equal to the average rate of formation of liver fibrosis per year, the rate of formation of liver fibrosis is considered average and antiviral therapy is carried out for 1–2 years. In cases where all indicators in a patient with CHB+C are below these, the rate of fibrosis is considered low and antiviral therapy is postponed.

EFFECT: invention provides determination of the average rate of formation of liver fibrosis per year in this category of patients, taking into account comorbidity, which, in turn, provides a differentiated approach in the choice of treatment tactics during antiviral therapy and, as a result, prevents adverse outcomes.

1 cl, 5 tbl, 3 ex